Latest information on COVID-19
Support teaching, research, and patient care.
The goal of the StEP AD Cohort is to use human genetic analyses to identify novel drug targets for Alzheimer's disease (AD). Dr. Greicius leads a multinational effort recruiting and characterizing two groups of subjects, those with the high-risk APOE4 gene who show no signs of AD despite being older than 75 and those who have early age-at-onset AD despite not having the high-risk APOE4 gene. The research team will perform whole-genome sequencing on 1000 subjects to find rare protective genetic variants in the "protected" APOE4 group and rare causal variants in the early-onset AD group.
As the Medical Director of the Stanford Center for Memory Disorders and Principal Investigator of the Stanford Extreme Phenotypes in Alzheimer's Disease (StEP AD) Cohort, Dr. Greicius' research focuses on elucidating the neurobiologic underpinnings of AD. His lab combines cutting edge brain imaging, "deep" phenotyping, and whole-genome sequencing of human subjects to identify novel pathways involved in AD pathogenesis. The goal of his work is to develop effective treatment for AD patients.